Although more mechanistic studies are required to understand the relationship between STK11 and PDEs in the progression of PDAC, the results reported herein also indicate a potential path for therapeutic intervention with Roflumilast for STK11 mutant pancreatic cancer patients. This evidence concerns the gene STK11 and familial pancreatic carcinoma.